Last update Aug. 17, 2019

プロテアーゼ

Compatible

Safe product and/or breastfeeding is the best option.

Enzymes which are able to hydrolyze proteins.
They are found in all living beings and are an important part of digestive enzymes: pancreatic (trypsin and chymotrypsin) and gastric (pepsin)..
They are orally used for gastrointestinal disorders and topically on wounds and burns. Some (chymotrypsin) are used in cataract surgery.
There is an increasing trend on type and therapeutic uses (Craik 2011). There is no evidence of its efficacy in the treatment of post-traumatic or post-surgical inflammations or in respiratory diseases.

At latest update relevant published data on excretion into breast milk were not found.

Because the small dose used and low plasma uptake of most topical dermatological and ophthalmological preparations it is unlikely that significant amounts of it will pass into breastmilk.
Its high molecular weight turns further improbable any excretion into breastmilk.
Due to its protein nature, when orally taken it is digested by the infant’s intestine, hence its absorption and passage to plasma should be nil.

The manufacturer considers it compatible with breastfeeding (AEMPS 2016).

Few studies with low levels of evidence on oral use of proteases to alleviate breast congestion have shown uneven results (ABM 2016, Mangesi 2016).

Alternatives

We do not have alternatives for プロテアーゼ since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

プロテアーゼ is Proteases in Japanese.

Is written in other languages:

プロテアーゼ is also known as

Tradenames

Main tradenames from several countries containing プロテアーゼ in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 23.000 - 35.000 daltons

References

  1. FDA. U.S. Food & Drug Administration Part 184.1- Substances added directly to human food affirmed as generally recognized as safe (GRAS). CFR. 2023 Consulted on Dec. 12, 2023 Full text (link to original source) Full text (in our servers)
  2. Mangesi L, Zakarija-Grkovic I. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2016 Jun 28;(6):CD006946. Abstract Full text (link to original source)
  3. Academy of Breastfeeding Medicine. Protocolo Clínico de la ABM #20, revisión 2016: Congestión Mamaria. Breastfeed Medicine. 2016 Abstract Full text (link to original source) Full text (in our servers)
  4. AEMPS - Salvat. Dertrase. Ficha técnica. 2016 Full text (in our servers)
  5. Berens P, Brodribb W. ABM Clinical Protocol #20: Engorgement, Revised 2016. Breastfeed Med. 2016 Abstract Full text (link to original source) Full text (in our servers)
  6. Craik CS, Page MJ, Madison EL. Proteases as therapeutics. Biochem J. 2011 Abstract
  7. Academy of Breastfeeding Medicine. Protocolo Clínico de la ABM #20, revisión 2009: Congestión Mamaria. Breastfeed Med. 2009 Full text (in our servers)

Total visits

2,332

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM